Please login to the form below

Not currently logged in

neurodegenerative diseases

This page shows the latest neurodegenerative diseases news and features for those working in and with pharma, biotech and healthcare.

Daily brief: Novartis spends big on ezcema,

Daily brief: Novartis spends big on ezcema,

MeiraGTx is developing therapies for diseases of the eye, salivary glands and central nervous system. ... Funds raised from the IPO will enable MeiraGTx to progress its product candidates to treat inherited rare eye diseases, xerostomia (‘dry mouth’)

Latest news

More from news
Approximately 3 fully matching, plus 51 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Takeda moves in neurodegenerative diseases and stem cell therapy. Meanwhile Takeda, ranked 4. ... The company has a focus in neurodegenerative diseases and a technology, Antibody Transport Vehicle (ATV) technology, which can enhance blood-brain barrier

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    Out-partnering deals included the $1.1bn licence to LEO for tralokinumab in skin diseases and the $1bn divestment to Pfizer of its late-stage small molecule anti-infective business. ... These deals were mainly early stage deals in the areas of

  • Deal Watch December 2016 Deal Watch December 2016

    510. Nuevolution (Denmark). Almirall (Spain). Research collaboration. RORγt inhibitors for inflammatory skin diseases and psoriatic arthritis. ... 320. Evotec (Germany). Celgene (US). Discovery collaboration. Induced pluripotent stem cells for

  • Deal Watch November 2016 Deal Watch November 2016

    equity investment, 2 year collaboration. 145. Chase Pharmaceuticals/ Allergan. fixed dose combinations for Alzheimer's and other neurodegenerative diseases inc CPC-201 (donepezil). ... acquisition - company. 125+. MorphoSys/ Leo Pharma. discovery and

  • Deal Watch February 2016 Deal Watch February 2016

    Pronutria's focus is on the development of therapeutics and nutritional supplements for diseases caused by amino acid imbalances. ... The company is developing oral biologics that deliver disease specific amino acid compositions to restore balance in

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 12 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
GK Strategy

GK is award-winning independent communications agency specialising in delivering impactful strategies for clients across the healthcare market....

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....